Cargando…

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation

The objective of this study was to compare outcomes between basiliximab and low-dose r-ATG in living donor kidney transplantation recipients with low immunological risk. Patients in the low-dose r-ATG group received 1.5 mg/kg of r-ATG for 3 days (total 4.5 mg/kg). Graft survival, patient survival, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sang Jin, Rhu, Jinsoo, Yoo, Heejin, Kim, Kyunga, Lee, Kyo Won, Park, Jae Berm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290680/
https://www.ncbi.nlm.nih.gov/pubmed/32370265
http://dx.doi.org/10.3390/jcm9051320
_version_ 1783545734645153792
author Kim, Sang Jin
Rhu, Jinsoo
Yoo, Heejin
Kim, Kyunga
Lee, Kyo Won
Park, Jae Berm
author_facet Kim, Sang Jin
Rhu, Jinsoo
Yoo, Heejin
Kim, Kyunga
Lee, Kyo Won
Park, Jae Berm
author_sort Kim, Sang Jin
collection PubMed
description The objective of this study was to compare outcomes between basiliximab and low-dose r-ATG in living donor kidney transplantation recipients with low immunological risk. Patients in the low-dose r-ATG group received 1.5 mg/kg of r-ATG for 3 days (total 4.5 mg/kg). Graft survival, patient survival, acute rejection, de novo donor specific antibody (DSA), estimated glomerular filtration rate (e-GFR) changes, and infection status were compared. Among 268 patients, 37 received r-ATG, and 231 received basiliximab. There was no noticeable difference in the graft failure rate (r-ATG vs. basiliximab: 2.7% vs. 4.8%) or rejection (51.4% vs. 45.9%). de novo DSA was more frequent in the r-ATG group (11.4% vs. 2.4%, p = 0.017). e-GFR changes did not differ noticeably between groups. Although most infections showed no noticeable differences between groups, more patients in the r-ATG group had cytomegalovirus (CMV) antigenemia and serum polyomavirus (BK virus) (73.0% vs. 51.9%, p = 0.032 in CMV; 37.8% vs. 15.6%, p = 0.002 in BK), which did not aggravate graft failure. Living donor kidney transplantation patients who received low-dose r-ATG and patients who received basiliximab showed comparable outcomes in terms of graft survival, function, and overall infections. Although CMV antigenemia, BK viremia were more frequent in the r-ATG group, those factors didn’t change the graft outcomes.
format Online
Article
Text
id pubmed-7290680
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72906802020-06-17 Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation Kim, Sang Jin Rhu, Jinsoo Yoo, Heejin Kim, Kyunga Lee, Kyo Won Park, Jae Berm J Clin Med Article The objective of this study was to compare outcomes between basiliximab and low-dose r-ATG in living donor kidney transplantation recipients with low immunological risk. Patients in the low-dose r-ATG group received 1.5 mg/kg of r-ATG for 3 days (total 4.5 mg/kg). Graft survival, patient survival, acute rejection, de novo donor specific antibody (DSA), estimated glomerular filtration rate (e-GFR) changes, and infection status were compared. Among 268 patients, 37 received r-ATG, and 231 received basiliximab. There was no noticeable difference in the graft failure rate (r-ATG vs. basiliximab: 2.7% vs. 4.8%) or rejection (51.4% vs. 45.9%). de novo DSA was more frequent in the r-ATG group (11.4% vs. 2.4%, p = 0.017). e-GFR changes did not differ noticeably between groups. Although most infections showed no noticeable differences between groups, more patients in the r-ATG group had cytomegalovirus (CMV) antigenemia and serum polyomavirus (BK virus) (73.0% vs. 51.9%, p = 0.032 in CMV; 37.8% vs. 15.6%, p = 0.002 in BK), which did not aggravate graft failure. Living donor kidney transplantation patients who received low-dose r-ATG and patients who received basiliximab showed comparable outcomes in terms of graft survival, function, and overall infections. Although CMV antigenemia, BK viremia were more frequent in the r-ATG group, those factors didn’t change the graft outcomes. MDPI 2020-05-02 /pmc/articles/PMC7290680/ /pubmed/32370265 http://dx.doi.org/10.3390/jcm9051320 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Sang Jin
Rhu, Jinsoo
Yoo, Heejin
Kim, Kyunga
Lee, Kyo Won
Park, Jae Berm
Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
title Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
title_full Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
title_fullStr Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
title_full_unstemmed Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
title_short Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
title_sort outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290680/
https://www.ncbi.nlm.nih.gov/pubmed/32370265
http://dx.doi.org/10.3390/jcm9051320
work_keys_str_mv AT kimsangjin outcomecomparisonbetweenlowdoserabbitantithymocyteglobulinandbasiliximabinlowrisklivingdonorkidneytransplantation
AT rhujinsoo outcomecomparisonbetweenlowdoserabbitantithymocyteglobulinandbasiliximabinlowrisklivingdonorkidneytransplantation
AT yooheejin outcomecomparisonbetweenlowdoserabbitantithymocyteglobulinandbasiliximabinlowrisklivingdonorkidneytransplantation
AT kimkyunga outcomecomparisonbetweenlowdoserabbitantithymocyteglobulinandbasiliximabinlowrisklivingdonorkidneytransplantation
AT leekyowon outcomecomparisonbetweenlowdoserabbitantithymocyteglobulinandbasiliximabinlowrisklivingdonorkidneytransplantation
AT parkjaeberm outcomecomparisonbetweenlowdoserabbitantithymocyteglobulinandbasiliximabinlowrisklivingdonorkidneytransplantation